Nasdaq Welcomes iRhythm Technologies, Inc. to The Nasdaq Stock Market

NEW YORK, Oct. 20, 2016 -- iRhythm Technologies, Inc. (Nasdaq:IRTC), a digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed, visited the Nasdaq MarketSite in Times Square today in celebration of its initial public offering (IPO) on The Nasdaq Stock Market. The company is based in San Francisco, CA.    

iRhythm Technologies, Inc. (Nasdaq:IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, visits the Nasdaq MarketSite in Times Square in celebration of its initial public offering (IPO).

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/21591a6c-4f3e-46d4-a89d-ea20d58ba66b

iRhythm combines its wearable biosensing technology with cloud-based data analytics and machine-learning capabilities. The company’s goal is to be the leading provider of first-line ambulatory electrocardiogram monitoring for patients at risk for arrhythmias. iRhythm’s unique platform, called the ZIO Service, may allow physicians to diagnose many arrhythmias more quickly and efficiently than traditional technologies and avoid multiple indeterminate tests. 

“As a digital health care company, we are very pleased to partner with Nasdaq.  iRhythm’s goal is to be the leading provider of first-line ambulatory monitoring for patients at risk for arrhythmias, so today’s listing is an exciting milestone as we focus on improving cardiac care,” said Kevin King, President and CEO, iRhythm Technologies. “We believe our Zio Service has the potential to supplant traditional ambulatory cardiac monitoring technology, become the primary first-line monitoring option for patients who are candidates for ambulatory cardiac monitoring and expand the market into new clinical use cases and indications.

“iRhythm is redefining the way cardiac arrhythmias are diagnosed and aspires to be the leading first-line ambulatory cardiac monitoring option for patients at risk for arrhythmias,” said Nelson Griggs, Executive Vice President, Listing Services, Nasdaq. “We congratulate iRhythm on this significant milestone and welcome them to the home of the world’s premier healthcare and biotechnology companies.”   

The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security, sector, or an overall investment strategy. Information about the company is provided by the company or comes from the company’s public filings and is not independently verified by Nasdaq.  Neither Nasdaq nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

About Nasdaq
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,700 listed companies with a market value of approximately $9.3 trillion and more than 18,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com  

- NDAQG -

Media Relations Contacts:

Stephanie Lowenthal
(646) 441-5073
[email protected]

Emily Pan
(646) 441-5120
[email protected]